Cargando…

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety

Budesonide MMX is a low bioavailability corticosteroid oral once-daily formulation, which has a controlled rate of release throughout the colon, thanks to the multimatrix (MMX) formulation. It has been available for a decade in the USA and Europe for the induction of remission in patients with activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maconi, Giovanni, Camatta, Deborah, Cannatelli, Rosanna, Ferretti, Francesca, Carvalhas Gabrielli, Anna, Ardizzone, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039041/ https://www.ncbi.nlm.nih.gov/pubmed/33854320 http://dx.doi.org/10.2147/TCRM.S263835

Ejemplares similares

An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
por: Ferretti, Francesca, et al.
Publicado: (2022)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Therapeutic Management of Adults with Inflammatory Bowel Disease and Malignancies: A Clinical Challenge
por: Ferretti, Francesca, et al.
Publicado: (2023)

OC.06.7 LOWER INCIDENCE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH NON-GUT SELECTIVE BIOLOGIC THERAPY
por: Ferretti, F., et al.
Publicado: (2021)

Ultrasonographic Evaluation of Intestinal Fibrosis and Inflammation in Crohn’s Disease. The State of the Art
por: Ferretti, Francesca, et al.
Publicado: (2021)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study
por: Rosiou, Konstantina, et al.
Publicado: (2021)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

Relevance of sonographic parameters for inflammatory bowel disease in children
por: Dell’Era, Alessandra, et al.
Publicado: (2023)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013)

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
por: Iborra, Marisa, et al.
Publicado: (2014)

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
por: Lichtenstein, Gary R.
Publicado: (2015)

MMX(®) technology and its applications in gastrointestinal diseases
por: Nardelli, Silvia, et al.
Publicado: (2017)

Modified Kudo classification can improve accuracy of virtual chromoendoscopy with FICE in endoscopic surveillance of ulcerative colitis
por: Cassinotti, Andrea, et al.
Publicado: (2020)

The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX(®) formulated delayed-release mesalamine
por: Yarlas, Aaron, et al.
Publicado: (2014)

Elderly-onset vs adult-onset ulcerative colitis: a different natural history?
por: Zammarchi, Irene, et al.
Publicado: (2020)

Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis
por: Zhou, Hong, et al.
Publicado: (2018)

Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
por: Shibuya, Tomoyoshi, et al.
Publicado: (2019)

The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study
por: Ferretti, Francesca, et al.
Publicado: (2022)

Use of Budesonide in the Treatment of Microscopic Colitis
por: Tangri, Vikram, et al.
Publicado: (2010)

Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis
por: Lin, Meisi, et al.
Publicado: (2021)

Nintedanib-Induced Colitis Treated Effectively With Budesonide
por: Amini, Afshin, et al.
Publicado: (2020)

Colon Delivery of Budesonide Using Solid Dispersion in Dextran for the Treatment and Secondary Prevention of Ulcerative Colitis in Rat
por: Varshosaz, Jaleh, et al.
Publicado: (2010)

Material designs and new physical properties in MX- and MMX-chain compounds
por: Yamashita, Masahiro, et al.
Publicado: (2014)

Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis
por: Naganuma, Makoto, et al.
Publicado: (2016)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
por: Naganuma, Makoto, et al.
Publicado: (2019)

Lack of effect of methotrexate in budesonide-refractory collagenous colitis
por: Münch, Andreas, et al.
Publicado: (2013)

Budesonide-Related Iatrogenic Cushing’s Syndrome in Microscopic Colitis
por: Tripathi, Kartikeya, et al.
Publicado: (2017)

Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis
por: Nardone, Olga Maria, et al.
Publicado: (2022)

MMX-I: data-processing software for multimodal X-ray imaging and tomography
por: Bergamaschi, Antoine, et al.
Publicado: (2016)

Pectin Film Coated Pellets for Colon-targeted Delivery of Budesonide: In-vitro/In-vivo Evaluation in Induced Ulcerative Colitis in Rat
por: Varshosaz, Jaleh, et al.
Publicado: (2012)

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p7d89pc69f8a413ptd1nqeln2l